Our platform combines proprietary, state-of-the-art antibody discovery and protein engineering technologies built to yield therapeutic candidates with compelling drug-like properties. Furthering our mission of unbiased, empirical discovery, the platform generates a wide array of molecules representing the broadest epitopic diversity for every target.

Our biology and immunology teams interrogate the antibodies with rigorous in vitro and in vivo screens to find the most promising drug format.  Antibody leads can also be combined as highly manufacturable bi- and multi-specifics, with valency, orientation and other properties tailored to the biology of each therapeutic application.  We test our therapeutic candidates as monotherapies and as components of combination regimens.

Our platform allows us to rapidly advance programs from idea generation to therapeutic candidate to the clinic.


StitchMabs is a proprietary high-throughput multispecific antibody screening platform.

We have discovered a technology that allows us to covalently link two or more monoclonal antibodies, antibody fragments, or other biologics into a variety of customized bi- and multi-specific formats in a matter of minutes. For example, we designed multi-specific antibodies that target and enhance activation of Natural Killer (NK) cells while simultaneously targeting tumor cells.


Sympleitope connects our drug candidate functionality with antibody design; it is our proprietary approach to epitope screening and selection.

We believe that epitope diversity is critical and that antibodies targeting different epitopes may “turn on” or “turn off” different immunological function. Accordingly, we developed proprietary in vitro systems to interrogate the pharmacological and biological attributes of antibodies binding to distinct epitopes. We can  generate both agonist and antagonist antibodies for both activating and inhibitory targets. Our first drug candidates are already demonstrating these differentiating insights.

Targeted Immunomodulation™

Tumor-targeted monoclonal antibodies generally require high target expression on the cancer cell, so many tumor targets with intermediate expression have not yet been successfully drugged. Checkpoint modulators have been successful in certain cancers, but the response is limited in most patients and there can be unacceptable side effects from systematic activation of the immune system. Our integrated protein engineering platform enables us to combine tumor recognition with in situ activation of immune effector cells in the tumor microenvironment.

Targeted immunomodulation represents a new class of therapeutics that leverages the specificity of tumor recognition with the power of immune activation in a single drug.